Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.80)
# 3,673
Out of 4,783 analysts
58
Total ratings
28.57%
Success rate
-26.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Assumes: Buy | $11 | $5.13 | +114.42% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $11.45 | +170.74% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.35 | +1,312.64% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $3.37 | +523.15% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $2.10 | +138.10% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $2.52 | +534.92% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $10 | $0.70 | +1,338.02% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $11.82 | +111.60% | 2 | May 14, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Neutral | n/a | $0.31 | - | 3 | Mar 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $200 | $1.29 | +15,403.88% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.15 | +508.70% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.35 | +640.74% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $9.31 | +544.47% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $0.45 | +1,231.26% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.50 | +185.71% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $0.69 | +34,707.83% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $14 | $0.84 | +1,566.67% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.38 | +20,958.17% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.96 | +303.23% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.53 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.05 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.40 | +328.57% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $9.65 | +117.62% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $300 | $0.29 | +105,163.16% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.85 | +1,900.00% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $20 | $0.76 | +2,539.22% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $635.83 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $60.68 | +46.67% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $114.00 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $1,000 | $0.91 | +109,790.11% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $1.76 | +18,990.91% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.74 | +381.28% | 1 | Mar 19, 2020 |
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $5.13
Upside: +114.42%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $11.45
Upside: +170.74%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.35
Upside: +1,312.64%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $3.37
Upside: +523.15%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $2.10
Upside: +138.10%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $2.52
Upside: +534.92%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $10
Current: $0.70
Upside: +1,338.02%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $11.82
Upside: +111.60%
Spruce Biosciences
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.31
Upside: -
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $200
Current: $1.29
Upside: +15,403.88%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.15
Upside: +508.70%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $1.35
Upside: +640.74%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $9.31
Upside: +544.47%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $0.45
Upside: +1,231.26%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.50
Upside: +185.71%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $0.69
Upside: +34,707.83%
Apr 28, 2023
Maintains: Buy
Price Target: $8 → $14
Current: $0.84
Upside: +1,566.67%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.38
Upside: +20,958.17%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $4.96
Upside: +303.23%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.53
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.05
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $1.40
Upside: +328.57%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $9.65
Upside: +117.62%
May 6, 2022
Initiates: Buy
Price Target: $300
Current: $0.29
Upside: +105,163.16%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $1.85
Upside: +1,900.00%
Nov 8, 2021
Upgrades: Buy
Price Target: $20
Current: $0.76
Upside: +2,539.22%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $635.83
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $60.68
Upside: +46.67%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $114.00
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $1,000
Current: $0.91
Upside: +109,790.11%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $1.76
Upside: +18,990.91%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $3.74
Upside: +381.28%